Abstract
The attempts to understand pancreatic cell-type specification and apply this information to direct the differentiation of insulin-producing cells from various sources have produced significant advances in the past few years. The steady progress of ES and stem/progenitor cell isolation, growth, and manipulation, combined with new technologies for genetic manipulations and lineage tracing, and a greater understanding of the endogenous factors required for β-cell differentiation and expansion have made the identification of alternative sources of insulin-producing cells a possibility. These fields are still relatively young, however, continued collaboration efforts between researchers of many different scientific disciplines will allow the common goal of generating alternative sources of β cells for therapeutic purposes to be achieved.
Original language | English (US) |
---|---|
Pages (from-to) | 149-162 |
Number of pages | 14 |
Journal | Endocrinology and Metabolism Clinics of North America |
Volume | 33 |
Issue number | 1 |
DOIs | |
State | Published - Mar 2004 |
Bibliographical note
Funding Information:Dr. Sussel is supported by the American Diabetes Association Career Development Award and National Institutes of Health (NIH) grant no. DK061248-0361. Michelle Doyle is supported by NIH grant no. T32-6M08730.